Palisade Bio received No Objection Letter from Health Canada for Phase 1 study
PremiumThe FlyPalisade Bio received No Objection Letter from Health Canada for Phase 1 study
1M ago
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal
Premium
Company Announcements
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal
2M ago
Palisade Bio provides update on Phase 1 trial of PALI-2108
Premium
The Fly
Palisade Bio provides update on Phase 1 trial of PALI-2108
2M ago
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
PremiumThe FlyStarbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
3M ago
Palisade Bio reports Q2 EPS ($3.32) vs ($7.93) last year
Premium
The Fly
Palisade Bio reports Q2 EPS ($3.32) vs ($7.93) last year
3M ago
Palisade Bio selects dose for upcoming Phase 1 study of PALI-2108
Premium
The Fly
Palisade Bio selects dose for upcoming Phase 1 study of PALI-2108
3M ago
Palisade Bio announces notice of allowance for Canadian patent on PALI-2108
PremiumThe FlyPalisade Bio announces notice of allowance for Canadian patent on PALI-2108
5M ago
Palisade Bio presents preclinical data on PALI-2108 at DDW 2024
Premium
The Fly
Palisade Bio presents preclinical data on PALI-2108 at DDW 2024
6M ago
Palisade Bio reports Q1 EPS ($4.59) vs ($8.13) last year
Premium
The Fly
Palisade Bio reports Q1 EPS ($4.59) vs ($8.13) last year
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100